A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
Abroad (travel likely)RecruitingPHASE1
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Conditions
Healthy Participants · Healthy Subjects · Healthy Volunteers · Autoimmune Diseases · Healthy Adult Participants · Atopic Dermatitis · Prurigo Nodularis
Locations
- Innovate Clinical Research, Waitara, New South Wales, Australia
- Cmax Clinical Research, Adelaide, South Australia, Australia
- Peking University Third Hospital, Beijing, Beijing Municipality, China
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
- Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China
- Xiangya Hospital of Central South University, Changsha, Hunan, China
- Suzhou Municipal Hospital, Suzhou, Jiangsu, China
- The First Hospital of China Medical University, Shenyang, Liaoning, China
- The Affiliated Hospital of Qingdao University Branch West Coast, Qingdao, Shandong, China
- Chengdu Second Peoples Hospital, Chengdu, Sichuan, China
- Optimal Clinical Trials Ltd, Auckland, New Zealand
- Pacific Clinical Research Network Auckland, Takapuna, New Zealand
- Lakeland Clinical Trials Wellington, Upper Hutt, New Zealand